<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan R Strosberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jaydira Del Rivero, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Whitcomb, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3717828179"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neuroendocrine neoplasms (NENs) comprise a heterogenous family of benign and malignant tumors. Neoplasms arising from neuroendocrine cells in the gastrointestinal system are termed gastroenteropancreatic NENs They are subdivided into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs)  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>).</p><p>Well-differentiated NETs often retain their ability to secrete peptides, amines, and other molecules, and functional NETs are defined as those that have a propensity to produce hormones and other vasoactive substances, which can give rise to various clinical syndromes [<a href="#rid1">1-8</a>]. Nonhormonal secretory products, such as chromogranin A, pancreastatin, and pancreatic polypeptide are often produced by both functional and nonfunctional NETs, and can serve as circulating serum tumor markers [<a href="#rid9">9</a>]. In addition to these hormonal and nonhormonal peptide markers, novel circulating RNA-based tests have been developed that are prognostic and potentially predictive for benefit from certain treatments.</p><p>This topic provides a brief summary of available tumor markers in gastroenteropancreatic NETs and offers guidance on the practical use of circulating tumor and hormonal markers in patients with gastroenteropancreatic well-differentiated NETs. The use of neuroendocrine tumor markers for specific clinical scenarios such as diagnosis of carcinoid syndrome, diagnostic evaluation for NENs, including those with an unknown primary site, post-treatment surveillance, and biochemical monitoring for individuals receiving therapy for advanced gastroenteropancreatic NENs, and the role of tumor markers for patients with high-grade NECs is described in detail elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization", section on 'Biochemical testing for carcinoid syndrome'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16667.html" rel="external">"Thymic neuroendocrine (carcinoid) tumors", section on 'Laboratory testing'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4883.html" rel="external">"Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site", section on 'Well-differentiated neuroendocrine tumor'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2516.html" rel="external">"Diagnosis and staging of small bowel neoplasms", section on 'Neuroendocrine tumors'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2527.html" rel="external">"Well-differentiated neuroendocrine tumors of the appendix", section on 'Assay of tumor markers'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'Tumor markers'</a>.)</p><p></p><p class="headingAnchor" id="H1214464087"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>A tumor biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathologic processes, or pharmacologic responses to a therapeutic intervention [<a href="#rid10">10</a>]. Biomarkers can be diagnostic, prognostic, or predictive.</p><p>This topic focuses mainly on the diagnostic use of several circulating biomarkers that may identify the presence of a NET, and inform the disease stage and extent, as well as the response to therapy.</p><p>Key metrics for the diagnostic use of biomarkers are sensitivity (the percentage of patients with the condition who are accurately detected by the test) and specificity (the percentage of control participants with normal test outcomes). The sensitivity and specificity of various biomarker cutoff levels can be depicted in a receiver-operating characteristic curve, where the area under the curve (AUC) represents the diagnostic power of the biomarker  (<a class="graphic graphic_figure graphicRef54239" href="/z/d/graphic/54239.html" rel="external">figure 1</a>). An AUC of 1.0 describes a perfect discriminatory marker, whereas an AUC &gt; 0.9 is generally considered an excellent metric. However, the performance characteristics of biomarkers are also dependent on the prevalence of true positive cases in the population being evaluated and perform best in subpopulations with high likelihood of the suspected disease or when the disease is at a more advanced stage. (See  <a class="medical medical_review" href="/z/d/html/2759.html" rel="external">"Glossary of common biostatistical and epidemiological terms", section on 'Measures of diagnostic test performance'</a>.)</p><p class="headingAnchor" id="H4069973851"><span class="h1">NONHORMONAL PEPTIDE TUMOR MARKERS</span></p><p class="headingAnchor" id="H1895700047"><span class="h2">Chromogranin A (CgA)</span><span class="headingEndMark"> — </span>CgA is a glycoprotein secreted by neurons and neuroendocrine cells [<a href="#rid11">11</a>]. It is a part of a family of granins, which are all precursors of biologically active substances [<a href="#rid11">11,12</a>]. CgA, specifically, is a precursor of pancreastatin, catestatin, and vasostatin I and II [<a href="#rid11">11</a>]. While all members of the granin family can be secreted by NETs, CgA is the marker most widely used in clinical practice.</p><p>Some studies report a high sensitivity [<a href="#rid12">12</a>], and specificity for CgA in patients with advanced NETs, both functional and nonfunctional [<a href="#rid13">13</a>]. A correlation has been reported between changes in CgA levels and progression or response to treatment, in many but not all studies [<a href="#rid14">14-21</a>], but especially in patients undergoing peptide receptor radiotherapy using 177-Lu Dotatate [<a href="#rid22">22</a>].</p><p>Test performance is better with advanced than with localized disease, and varies according to site and disease burden. Reported sensitivity and specificity rates for localized tumors are 32 to 92, and 10 to 96 percent, respectively [<a href="#rid14">14,23-30</a>]. A meta-analysis of 13 heterogeneous studies on CgA as a diagnostic marker that compared patients with NETs versus healthy controls reported an overall sensitivity of 73 percent, a specificity of 95 percent, and a receiver-operating characteristic area under the curve of 0.90 [<a href="#rid30">30</a>]. Sensitivity is lower in patients with colorectal and lung NETs compared with those who have gastroenteropancreatic NETs as tumors originating in those sites more commonly manifest intense secretory activity (eg, small bowel NETs) [<a href="#rid31">31,32</a>].</p><p>However, there are several important caveats to take into account when CgA is used as a tumor marker for NETs, that limit its utility:</p><p class="bulletIndent1"><span class="glyph">●</span>Several medications, notably proton pump inhibitors (PPI), and some foods increase CgA levels, leading to false positive results  (<a class="graphic graphic_table graphicRef73287" href="/z/d/graphic/73287.html" rel="external">table 2</a>); CgA should ideally be measured in a fasting state, and no sooner than two weeks after discontinuation of the PPI [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CgA levels are often elevated in nonneoplastic conditions such as chronic atrophic gastritis, renal failure, and inflammatory diseases  (<a class="graphic graphic_table graphicRef73287" href="/z/d/graphic/73287.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A recognized international standard for CgA assay is not available, and multiple CgA tests exist that use different assays, have widely divergent normal thresholds, and varying degrees of accuracy [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sensitivity is limited in cases with localized disease or low metastatic tumor burden [<a href="#rid31">31,35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caution is needed when using serum CgA as a marker indicative of changing tumor burden in patients treated with somatostatin analogs. These agents significantly reduce plasma CgA levels, and this change may reflect diminished hormonal synthesis and release from tumor cells rather than a reduction in tumor mass [<a href="#rid36">36</a>].</p><p></p><p>As a result of all of these issues, the utility of CgA, particularly as an aid to diagnosis of NETs, in post-treatment surveillance following resection of localized disease, or in following the response to treatment for advanced disease, is limited. An important point is that if serial measurements of CgA are used in patients with advanced NETs, they should be performed using the same assay.</p><p class="headingAnchor" id="H162973233"><span class="h2">Neuron-specific enolase</span><span class="headingEndMark"> — </span>Neuron-specific enolase (NSE) is a soluble protein present in the cytoplasm of neurons and neuroendocrine cells [<a href="#rid37">37</a>]. NSE is neither sensitive nor specific for NETs; in two series totaling over 200 patients with gastroenteropancreatic NETs, sensitivity and specificity rates were 39 to 43, and 65 to 73 percent, respectively for differentiating NETs from nonendocrine tumors [<a href="#rid38">38,39</a>]. When elevated in NETs, however, high levels of NSE can be a marker indicating aggressive disease that portends a poor prognosis [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H3204273804"><span class="h2">Pancreatic polypeptide</span><span class="headingEndMark"> — </span>Pancreatic polypeptide (PP) is an oligopeptide primarily secreted by a subset of pancreatic islet cells in the head of the pancreas that do not produce insulin, glucagon, or somatostatin [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/2595.html" rel="external">"Pancreatic polypeptide, peptide YY, and neuropeptide Y", section on 'Tissue distribution'</a>.)</p><p>PP is most commonly elevated in patients with pancreatic NETs and when elevated, it can serve as a tumor marker. It can be elevated in other types of gastrointestinal NETs as well [<a href="#rid13">13</a>]. However, in general, PP has limited clinical utility in patients with gastroenteropancreatic NETs due to its low and variable sensitivity [<a href="#rid23">23,42</a>].</p><p class="headingAnchor" id="H2697258236"><span class="h2">Pancreastatin</span><span class="headingEndMark"> — </span>Pancreastatin is a peptide derived from proteolytic processing of CgA [<a href="#rid43">43</a>]. Pancreastatin serum levels are reportedly uninfluenced by PPIs, indicating that they may be a preferred tumor marker over CgA in patients being treated with PPIs. Some studies have reported improved correlation of pancreastatin with disease progression or response compared with CgA [<a href="#rid44">44-46</a>]; however, sensitivity (46 to 81 percent) is still limited [<a href="#rid24">24,25,47,48</a>]. Furthermore, while pancreastatin might offer some advantages over CgA, particularly in patients using PPIs, the data supporting its use derive from a small number of institutions.</p><p class="headingAnchor" id="H210850402"><span class="h2">Role of nonhormonal tumor markers in clinical practice</span><span class="headingEndMark"> — </span>Despite a multitude of published studies evaluating multiple circulating tumor markers in NETs, guidelines have increasingly deemphasized their role in clinical care. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Routine measurement of CgA in patients with newly diagnosed NETs of the gastrointestinal tract, lung thymus, and nonfunctional pancreatic NETs is now considered a category III recommendation (controversial) by the National Comprehensive Cancer Network [<a href="#rid49">49</a>]. Following potentially curative treatment, the utility of serial monitoring of biochemical markers as an indicator of recurrent disease, and its use for monitoring disease response or progression in patients with metastatic disease are also described as category III recommendations, to be performed only "as clinically indicated."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most recent North American Neuroendocrine Tumor Society guidelines on diagnosis and post-treatment surveillance for midgut and pancreatic NETs likewise do not recommend routine use of CgA for diagnosis, post-treatment surveillance, or monitoring the response to therapy [<a href="#rid50">50,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, the consensus among the investigators in the Commonwealth Neuroendocrine Tumour Collaboration is that the role of these tumor markers in surveillance after surgical resection of a NET is limited due to their relatively poor sensitivity and specificity [<a href="#rid52">52,53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific recommendations for using nonhormonal tumor markers in clinical practice are not available from the European Neuroendocrine Tumour Society [<a href="#rid54">54</a>].</p><p></p><p>There are multiple reasons for these positions, including the clinical perception that levels often fluctuate without corresponding changes in scans or clinical status, the widespread use of PPIs in the population which falsely elevate CgA results, and lack of evidence that tumor markers provide significant marginal benefit beyond radiographic and clinical evaluations. CgA is particularly not useful in the evaluation of patients with type I gastric NETs that are associated with atrophic gastritis, a condition in which CgA is usually high and where variations in CgA levels may fluctuate in ways that do not reflect the patient's burden of disease. (See  <a class="medical medical_review" href="/z/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Stomach'</a>.)</p><p>Given the issues with sensitivity and specificity, changes in tumor marker levels that do not correlate with clinical or radiographic findings can contribute to patient anxiety and to unwarranted treatment decisions.</p><p>In practice, the utility of CgA in the management of gastroenteropancreatic NETs is limited.</p><p class="headingAnchor" id="H3840473680"><span class="h3">Our recommended approach</span><span class="headingEndMark"> — </span>The following reflects our approach to use of nonhormonal tumor markers, which is consistent with consensus-based guidelines:</p><p class="bulletIndent1"><span class="glyph">●</span>In general, serial measurements of CgA and/or other nonhormonal tumor markers are most useful in patients with metastatic NETs and highly elevated levels of the marker because upward trends in CgA levels in these patients are more likely to be reflective of disease burden rather than being false-positives. Whenever we do measure tumor marker levels, we usually obtain them in conjunction with radiographic imaging, typically every 6 to 12 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We generally do not advocate using CgA or any other nonhormonal tumor marker as a diagnostic test for NETs, or for post-treatment surveillance after surgical treatment of a non-metastatic NET. Histopathologic evaluation of tissue by a dedicated pathologist remains the gold standard for the diagnosis of an NET.</p><p></p><p class="headingAnchor" id="H3506074521"><span class="h1">HORMONES THAT LEAD TO CLINICAL SYNDROMES</span><span class="headingEndMark"> — </span>Unlike nonhormonal tumor markers, hormone measurements in the blood and/or urine can serve an important role in identifying and following patients with clinical syndromes that result from secretion of certain hormones, in the differential diagnosis of symptoms such as chronic unexplained diarrhea, and for evaluating risk for carcinoid heart disease.</p><p class="headingAnchor" id="H4251136897"><span class="h2">Serotonin and 5-hydroxyindoleacetic acid (5-HIAA)</span><span class="headingEndMark"> — </span>Serotonin (5-hydroxytryptamine) is an amine derivative secreted by the enterochromaffin cells of the small intestine, and is the main hormone implicated in the carcinoid syndrome [<a href="#rid12">12,13,55,56</a>]. Since the liver completely metabolizes serotonin produced from small bowel NETs after delivery by the portal system, elevated circulating serotonin levels occur only in patients with metastatic disease, or when the portal vein is bypassed (eg, ovarian primaries) [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome", section on 'Pathophysiology'</a>.)</p><p>The systemic sequelae of increased serotonin levels, carcinoid syndrome, is predominantly diagnosed in patients with metastatic small intestine NETs. The major symptoms of carcinoid syndrome are diarrhea and flushing: the secretory diarrhea observed in carcinoid syndrome is directly caused by serotonin secretion, whereas multiple vasoactive substances, including tachykinins and histamine, are thought to be involved in flushing. (See  <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome", section on 'Clinical features'</a>.)</p><p>Carcinoid heart disease is characterized by fibrosis and thickening of tricuspid and pulmonary valves, and is a long-term consequence of elevated serotonin levels [<a href="#rid58">58,59</a>]. The risk of carcinoid heart disease development correlates closely with serotonin elevations [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/8135.html" rel="external">"Carcinoid heart disease", section on 'Role of serotonin'</a>.)</p><p>A problem with measurement of blood serotonin is that it is relatively nonspecific and can be affected not only by diet but also by platelet release during venipuncture and specimen processing (see  <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization", section on 'Blood serotonin concentration'</a>). Therefore, 24-hour urine measurements of 5-HIAA, a serotonin metabolite  (<a class="graphic graphic_figure graphicRef51368" href="/z/d/graphic/51368.html" rel="external">figure 2</a>), are preferred over blood serotonin levels, although they are cumbersome, and disliked by patients.</p><p>Several foods and medications can affect 5-HIAA levels, and it is important for patients to be provided with instructions on foods and medications to avoid during and for several days before the urine collection  (<a class="graphic graphic_table graphicRef79968" href="/z/d/graphic/79968.html" rel="external">table 3</a>) [<a href="#rid61">61</a>]. Other conditions such as malabsorption, celiac disease, and renal failure can affect 5-HIAA levels.</p><p>Measurement of urinary excretion of 5-HIAA is generally most useful in patients with primary midgut (jejunoileal, appendiceal, ascending colon) NETs, which produce the highest levels of serotonin. Foregut (gastroduodenal, bronchus) and hindgut (transverse, descending, and sigmoid colon, rectum, genitourinary) NETs only rarely secrete serotonin; they lack the enzyme dopa decarboxylase and cannot convert 5-hydroxytryptophan (5-HT) into serotonin and, therefore, into 5-HIAA  (<a class="graphic graphic_figure graphicRef51368" href="/z/d/graphic/51368.html" rel="external">figure 2</a>) [<a href="#rid62">62,63</a>]. Foregut tumors may produce 5-HT (and histamine) instead of serotonin. However, there is no commercially available assay for urinary 5-HT. (See  <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts"</a>.)</p><p>Elevation in excretion of urinary 5-HIAA is highly sensitive and specific for midgut tumors that have metastasized to the liver, and produce the carcinoid syndrome. Levels may be normal even in the presence of carcinoid syndrome, particularly if diarrhea is absent, but this is rare [<a href="#rid64">64</a>].</p><p>However, urinary 5-HIAA is relatively insensitive for isolated non-metastatic midgut NETs; any elevation in urinary 5-HIAA in this setting is likely to be a false positive test [<a href="#rid14">14,64-66</a>].</p><p>Plasma 5-HIAA levels can also be obtained from several laboratories, and reportedly correlate closely with urine 5-HIAA [<a href="#rid67">67-69</a>]. Plasma 5-HIAA measurement is a reasonable option, particularly for patients who have difficultly providing 24-hour urine specimens, although published experience with this assay is confined to a small number of institutions. (See  <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization", section on 'Blood serotonin concentration'</a>.)</p><p class="headingAnchor" id="H2569222931"><span class="h3">Clinical utility</span><span class="headingEndMark"> — </span>Measurements of 5-HIAA can be useful in several scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with chronic, unexplained diarrhea and/or flushing. An elevated level of 5-HIAA (with appropriate dietary restrictions) is suggestive of carcinoid syndrome and should lead to further radiographic workup. (See  <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization", section on 'Urinary excretion of 5-HIAA'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring of patients with metastatic (typically midgut) NETs and those with carcinoid syndrome:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Highly elevated levels of 5-HIAA are predictive of heightened risk for carcinoid heart disease and need for echocardiographic screening [<a href="#rid58">58,59,70</a>], although there is no absolute cutoff value to predict the development of carcinoid heart disease. Because of this, even in the absence of flushing/diarrhea (carcinoid syndrome), we periodically measure 5-HIAA in most patients with metastatic midgut NETs for the purpose of identifying patients at risk for carcinoid heart disease. The addition of amino-terminal pro-brain natriuretic peptide increases the accuracy of the risk prediction (with an receiver-operating characteristic area under the curve of 0.82-0.86 [<a href="#rid71">71,72</a>]). (See <a class="local">'Definitions'</a> above and  <a class="medical medical_review" href="/z/d/html/8135.html" rel="external">"Carcinoid heart disease", section on 'When and how to initially test for carcinoid heart disease'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with advanced serotonin-producing tumors with highly elevated levels of 5-HIAA are at risk for developing carcinoid crisis during surgery/anesthesia. For patients undergoing surgery for metastatic NET who have a history of carcinoid syndrome, prophylactic preoperative use of <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> is optional, especially in those who are already receiving a long-acting somatostatin analog, but almost certainly unnecessary in patients without carcinoid syndrome. However, octreotide should be readily available intraoperatively for "as needed" intravenous use for patients who develop hemodynamic instability during surgery. (See  <a class="medical medical_review" href="/z/d/html/16638.html" rel="external">"Treatment of the carcinoid syndrome", section on 'Carcinoid crisis: prevention and management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with NETs who have diarrhea and elevated 5-HIAA (ie, carcinoid syndrome) may benefit symptomatically from efforts to reduce tumor bulk and/or serotonin using somatostatin analogs, cytoreductive treatments such as liver embolization or peptide receptor radioligand therapy, or <a class="drug drug_general" data-topicid="112170" href="/z/d/drug information/112170.html" rel="external">telotristat</a>, an inhibitor of the enzyme tryptophan hydroxylase, a rate limiting step in the conversion of tryptophan to serotonin within tumor cells. (See  <a class="medical medical_review" href="/z/d/html/16638.html" rel="external">"Treatment of the carcinoid syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Conversely, patients with advanced NETs who have relatively normal 5-HIAA may have alternative explanations for their diarrhea such as bile malabsorption from surgery or pancreatic exocrine insufficiency, and may not benefit from specific therapies targeting the NET.</p><p></p><p>For most patients, measurement of 5-HIAA can be performed roughly every 6 to 12 months; more frequent measurements are generally not helpful. Outside of midgut NETs (urine 5-HIAA should not be measured unless there are symptoms suggestive of carcinoid syndrome). Patients undergoing 5-HIAA assay should be educated about the foods and medications to avoid before undertaking the test  (<a class="graphic graphic_table graphicRef79968" href="/z/d/graphic/79968.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H3326912722"><span class="h2">Hormones associated with pancreatic NETs</span><span class="headingEndMark"> — </span>Multiple peptide hormones are associated with pancreatic NET syndromes such as Zollinger Ellison Syndrome (ZES), insulinoma syndrome, glucagonoma syndrome, and VIPoma syndrome. In general, we recommend that hormone levels be evaluated based on clinical symptoms only. We do not test nonspecific panels of hormone levels for all patients with nonfunctioning tumors, which account for the majority of pancreatic NETs. (See  <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.)</p><p>Consistent with guidelines from the National Comprehensive Cancer Network, we periodically assay serum hormone levels that are initially elevated every 6 to 12 months in conjunction with radiographic imaging following resection of a functioning pancreatic NET [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H2341964599"><span class="h3">Gastrin</span><span class="headingEndMark"> — </span>Gastrin is a peptide hormone secreted by the G-cells of the pyloric antrum, duodenum, and pancreas. It is involved in the stimulation of gastric acid release [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H4182909208"><span class="h4">Gastrinomas</span><span class="headingEndMark"> — </span>Gastrin-secreting tumors, known as gastrinomas, are one of the most common functional NETs of the pancreas and duodenum. The clinical consequence of a gastrinoma is ZES, characterized by heartburn, diarrhea, and chronic multiple peptic ulcers. (See  <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a>.)</p><p>A serum gastrin value greater than 10 times the upper limit of normal (1000 pg/mL) in the presence of a gastric pH below 2 is diagnostic of ZES. While basal acid output measurement used to be described as a diagnostic test, this test is rarely performed; however, a gastric pH level can be measured during esophagogastroduodenoscopy and should be low in untreated ZES. (See  <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis", section on 'Serum gastrin concentration'</a>.)</p><p>Fasting gastrin can be physiologically elevated in chronic atrophic gastritis, in patients taking proton pump inhibitors (PPI), and with Helicobacter pylori infection [<a href="#rid74">74</a>]. PPIs should ideally be discontinued 10 to 14 days prior to measuring fasting gastrin; however, this can be difficult for patients whose symptoms are highly suspicious for ZES. High doses of H2 blockers can be used in place of PPIs to prevent peptic complications [<a href="#rid56">56</a>].</p><p>If the gastrin level is between the upper limit of normal and 1000 pg/mL, a <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">secretin</a> test can be performed [<a href="#rid75">75</a>], and is considered positive if gastrin rises more than 120 pg/mL, with a diagnostic sensitivity of 94 percent and specificity of 100 percent [<a href="#rid76">76</a>]. However, in the era of multiphasic computed tomography scans, somatostatin receptor imaging positron emission tomography scans, and endoscopic ultrasound, a secretin test is rarely necessary to establish a diagnosis of gastrinoma. (See  <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis", section on 'Secretin stimulation test'</a>.)</p><p>In patients with advanced gastrinoma, gastrin can be monitored as a tumor marker, although it is important to note that PPIs will elevate gastrin modestly in nearly all cases and may therefore confound results. Gastrin levels are also measured every two to three years in asymptomatic patients with Multiple Endocrine Neoplasia type 1 (starting at age 16 or when clinical symptoms are present regardless of age) since gastrinomas are the most common NETs associated with this hereditary syndrome [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Monitoring for MEN1-associated tumors'</a>.)</p><p class="headingAnchor" id="H217167023"><span class="h4">Gastric NETs</span><span class="headingEndMark"> — </span>A baseline gastrin level should also be measured in patients with gastric NETs: an elevated gastrin (ideally off PPI) is indicative of either type I (underlying atrophic gastritis; common) or type II (underlying gastrinoma; rare), whereas a normal gastrin level suggests type III (sporadic) gastric NET. In contrast to type II tumors, arising in the setting of ZES, for type I gastric NETs, there is no need to repeat gastrin levels after baseline collection. (See  <a class="medical medical_review" href="/z/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Stomach'</a>.)</p><p class="headingAnchor" id="H2884440702"><span class="h3">Insulin</span><span class="headingEndMark"> — </span>Insulin is a peptide secreted by the pancreatic islet β cells, which plays a key role in glucose metabolism and uptake [<a href="#rid78">78</a>]. Insulinomas are insulin-producing-tumors that are typically small, and almost always localized to the pancreas; they are the most common functioning NET in that organ. However, many other conditions such as diabetes mellitus type 2, impaired glucose tolerance, and administration of exogenous insulin can cause elevated insulin levels [<a href="#rid73">73</a>].</p><p>Insulinomas should be suspected in a patient who exhibits "Whipple's triad," which is defined as symptoms or signs of hypoglycemia, a low plasma level of glucose, and an improvement of these symptoms after the administration of glucose [<a href="#rid79">79</a>]. The gold standard test for diagnosis of an insulinoma is the 72-hour fasting test, which should measure insulin, proinsulin, and C-peptide. Insulin, C-peptide, and proinsulin are elevated in insulinoma, whereas patients who are injecting excessive amounts of exogenous insulin typically have elevated insulin concentrations but suppressed C-peptide and proinsulin concentrations  (<a class="graphic graphic_table graphicRef56314" href="/z/d/graphic/56314.html" rel="external">table 4</a>). Rarely, low levels of insulin and C-peptide might be caused by an insulin growth factor 2-producing non-islet cell tumor. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma"</a> and  <a class="medical medical_review" href="/z/d/html/1782.html" rel="external">"Noninsulinoma pancreatogenous hypoglycemia syndrome"</a>.)</p><p>Several studies have shown that the sensitivity of this supervised 72-hour fasting test for insulinoma detection is 100 percent [<a href="#rid80">80-83</a>]. Proinsulin levels can be particularly elevated in patients with malignant/advanced insulinoma [<a href="#rid84">84,85</a>].</p><p class="headingAnchor" id="H3156174224"><span class="h3">Glucagon</span><span class="headingEndMark"> — </span>Glucagon is a peptide hormone produced by pancreatic alpha cells, which has an antagonistic effect to insulin, stimulating gluconeogenesis and glycogenolysis. Glucagonomas are rare functioning NETs that secrete glucagon. These pancreatic tumors are typically large (&gt;3 cm) and most (50 to 80 percent) are metastatic at diagnosis [<a href="#rid86">86</a>]. Glucagonoma syndrome is characterized by hyperglycemia, glossitis, cachexia, and the distinctive skin eruption necrolytic migratory erythema.</p><p>The diagnosis of a glucagonoma requires the demonstration of elevated fasting glucagon levels. However, some glucagonomas are associated with serum levels of the peptide in the "physiologically elevated" range, even in the presence of necrolytic migratory erythema. Thus, in patients with the classic syndrome, a normal serum glucagon does not exclude a glucagonoma. (See  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome", section on 'Serum glucagon'</a>.)</p><p class="headingAnchor" id="H2369704592"><span class="h3">Vasoactive intestinal peptide</span><span class="headingEndMark"> — </span>Vasoactive intestinal peptide (VIP) is a peptide hormone released by pancreatic cells It derives its name from its splanchnic vasodilatory activity that regulates blood flow in the gastrointestinal tract, but it also stimulates contraction of enteric smooth muscles cells and pancreatic epithelial cell (exocrine) secretion, and inhibits gastric acid secretion. VIPomas, which are VIP secreting tumors, are rare and most commonly found in the pancreatic tail [<a href="#rid87">87</a>]. The VIPoma syndrome is characterized by severe watery diarrhea (&gt;700 mL per day), typically leading to electrolyte imbalances including hypokalemia, acidosis, and achlorhydria. VIPomas have metastasized at the time of diagnosis in more than 80 percent of cases [<a href="#rid86">86</a>]. The diagnosis is established when patients have characteristic symptoms, pathologic evidence of disease, and elevated VIP levels. (See  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H1089670936"><span class="h2">Other hormones</span><span class="headingEndMark"> — </span>Gastroenteropancreatic NETs can secrete numerous other hormones including parathyroid hormone (PTH) and PTH-related protein, which cause hypercalcemia; adrenocorticotropic hormone (ACTH), which can lead to ACTH dependent Cushing's syndrome; and others. In some cases, NETS will secrete multiple hormones leading to multiple syndromes associated with their oversecretion. In all cases, clinical and laboratory findings should guide decisions on which hormone levels to measure.</p><p class="headingAnchor" id="H1780907122"><span class="h1">NOVEL CIRCULATING BIOMARKERS</span></p><p class="headingAnchor" id="H414821369"><span class="h2">NETest</span><span class="headingEndMark"> — </span>The NET-related transcript-based evaluations test (NETest) is a novel RNA-based assay that has been reported to be superior to chromogranin A (CgA) in multiple metrics. However, the optimal way to integrate this test into clinical practice is not yet established. A key question is whether adjustments in treatment should be made solely based on changes in the marker level or is radiographic confirmation required to confirm tumor progression or response.</p><p>Tumor transcripts can be detected in the circulation and measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). NETest is a multianalyte qRT-PCR RNA-based essay that encompasses the simultaneous measurement of 51 different biologically relevant transcripts involved in NET proliferation, signaling, and secretion, as well as genes reported to have a defined association with tumor initiation and metastases [<a href="#rid88">88,89</a>]. The assay gives a single readout; scores range from 0 to 100 percent in 16 increments indicating disease activity risk. Thresholds of 0 to 20 are usually considered within normal range (minimal activity). while elevated levels (typically ≥80 percent), are considered to indicate high activity, and levels between 40 and 80 percent are considered intermediate. A cutoff score ≤40 percent can be used to rule in stable disease while a score &gt;40 rules out stable disease [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H3520412892"><span class="h3">Clinical utility</span><span class="headingEndMark"> — </span>The available data suggest that high activity levels for NETest outperforms other NET biomarkers including CgA for diagnosis of neuroendocrine neoplasms [<a href="#rid91">91-99</a>], prediction of clinical disease stability/progression/tumor burden [<a href="#rid89">89,97-102</a>], and determination of therapeutic efficacy of somatostatin analog therapy and following peptide receptor radiotherapy [<a href="#rid100">100,101,103-106</a>]. A meta-analysis of ten studies evaluating the utility of NETest as a diagnostic and monitoring tool came to the following conclusions [<a href="#rid90">90</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The diagnostic accuracy of NETest was high (95 percent) with a specificity of 95 to 98 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mean estimated diagnostic odds ratio was very high (5853), the positive likelihood ratio was 195, and the negative likelihood ratio was 0.06. (See  <a class="medical medical_review" href="/z/d/html/2759.html" rel="external">"Glossary of common biostatistical and epidemiological terms", section on 'Likelihood ratio'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The NETest was 84 to 85 percent accurate in differentiating stable disease from progressive disease on disease monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As an interventional/response biomarker, the accuracy was 94 to 97 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of all studies indicated an area under the curve of 0.954.</p><p></p><p>However, the optimal way to integrate this test into clinical practice is unclear:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients undergoing treatment for advanced disease, a key question is whether adjustments in treatment should be made solely based on changes in the marker level or is radiographic confirmation required? Ideally, studies should confirm that scans can be delayed in patients with stable (or improving) NETest values in order to further validate the practical role of this test before it can be incorporated into routine clinical practice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal cutoff to define disease progression (ie, &gt;40 or &gt;80 percent) is not established [<a href="#rid90">90,101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While these circulating transcripts represent an emerging opportunity for diagnosis of NETs, whether they can be used to differentiate NETs from other tumors (especially adenocarcinomas [<a href="#rid95">95</a>]) requires further study [<a href="#rid13">13</a>]. There are also concerns about the availability and cost of this biomarker for the diagnosis of NETs in clinical practice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirmation of these observations in larger series and by other groups is needed.</p><p></p><p class="headingAnchor" id="H2304177907"><span class="h2">Peptide receptor radiotherapy prediction quotient</span><span class="headingEndMark"> — </span>This test uses a similar methodology to the NETest to evaluate gene expression involved in metabolism and growth factor expression. When combined with tumor grade, it has been reported to be highly predictive of benefit (response or disease stabilization) with 177Lu-Dotatate in NETs [<a href="#rid59">59,103,107</a>]. Validation studies are underway.</p><p class="headingAnchor" id="H2858524539"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86735.html" rel="external">"Patient education: Carcinoid syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H141634643"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H2637280200"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Gastroenteropancreatic neuroendocrine tumors (NETs) have the ability to secrete peptides, amines, and other molecules. Functional NETs are defined as those that produce hormones and other vasoactive substances, which can give rise to various clinical syndromes. In addition, nonhormonal secretory products, such as chromogranin A (CgA), pancreastatin, and pancreatic polypeptide (PP) are often produced by both functional and nonfunctional NETs, and can serve as circulating serum tumor markers. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, the limitations of many tumor markers in terms of sensitivity, specificity  (<a class="graphic graphic_table graphicRef73287" href="/z/d/graphic/73287.html" rel="external">table 2</a>), and prognostic utility have led to a deemphasis of nonhormonal tumor makers such as CgA in many guidelines, including those of the National Comprehensive Cancer Network (NCCN) and North American Neuroendocrine Tumor Society. Given their limited sensitivity and specificity, changes in tumor marker levels that do not correlate with clinical or radiographic findings can contribute to false conclusions regarding changes in disease burden and to unwarranted treatment decisions. (See <a class="local">'Nonhormonal peptide tumor markers'</a> above.)</p><p></p><p class="bulletIndent1">For all of these reasons, we generally do not advocate using nonhormonal tumor markers such as CgA, PP, or pancreastatin for routine monitoring of patients. They should never be used as diagnostic tests in patients lacking pathologic evidence of disease nor should treatment ever be administered based solely upon elevated levels without a pathologic confirmation of the presence of disease. (See <a class="local">'Nonhormonal peptide tumor markers'</a> above.)</p><p></p><p class="bulletIndent1">Unlike nonhormonal tumor markers, hormone measurements in the blood and/or urine can serve an important role in identifying and following patients with NETs who have clinical syndromes that result from secretion of certain hormones, in the differential diagnosis of symptoms such as chronic diarrhea, and for evaluating risk for carcinoid crisis and heart disease. (See <a class="local">'Hormones that lead to clinical syndromes'</a> above.)</p><p></p><p class="bulletIndent1">For diagnostic testing, measurements of specific hormones that contribute to a clinical syndrome (eg, insulin for insulinomas, glucagon for glucagonomas) should usually be symptom based. We do not test nonspecific panels of hormone markers for patients with nonfunctioning tumors, which account for the majority of pancreatic NETs. Consistent with guidelines from the NCCN, we periodically assay serum hormone levels that are initially elevated every 6 to 12 months in conjunction with radiographic imaging following resection of a functioning pancreatic NET. (See <a class="local">'Hormones associated with pancreatic NETs'</a> above.)</p><p></p><p class="bulletIndent1">However, regardless of symptoms, we recommend periodically checking urinary 5-hydroxyindoleacetic acid (5-HIAA) levels in most patients with metastatic small intestinal NETs. For other patients, the value of periodic assessment of 5-HIAA levels is uncertain. For most patients, we measure 5-HIAA approximately every 6 to 12 months; more frequent measurements are generally not helpful. Patients should be educated about the medications and foods that can interfere with 5-HIAA measurement, and avoid these substances prior to urine collection  (<a class="graphic graphic_table graphicRef79968" href="/z/d/graphic/79968.html" rel="external">table 3</a>). (See <a class="local">'Serotonin and 5-hydroxyindoleacetic acid (5-HIAA)'</a> above.)</p><p></p><p class="bulletIndent1">Plasma 5-HIAA measurement is a reasonable option, particularly for patients who have difficultly providing 24-hour urine specimens, although published experience with this assay is confined to a small number of institutions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The NETest is a novel RNA-based assay that has been reported to be superior to CgA in multiple metrics. The available data suggest that high activity levels for NETest outperforms other NET biomarkers including CgA for prediction of clinical disease stability/progression/tumor burden, and determination of therapeutic efficacy of somatostatin analog therapy and following peptide receptor radiotherapy. However, the optimal way to integrate this test into clinical practice is not yet established. (See <a class="local">'NETest'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin 2018; 68:471.</a></li><li><a class="nounderline abstract_t">Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991; 66:711.</a></li><li><a class="nounderline abstract_t">Jensen RT. Gastrinomas: advances in diagnosis and management. Neuroendocrinology 2004; 80 Suppl 1:23.</a></li><li><a class="nounderline abstract_t">VERNER JV, MORRISON AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 1958; 25:374.</a></li><li><a class="nounderline abstract_t">van Beek AP, de Haas ER, van Vloten WA, et al. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol 2004; 151:531.</a></li><li><a class="nounderline abstract_t">Öberg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg 2018; 7:20.</a></li><li><a class="nounderline abstract_t">Davis Z, Moertel CG, McIlrath DC. The malignant carcinoid syndrome. Surg Gynecol Obstet 1973; 137:637.</a></li><li><a class="nounderline abstract_t">von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993; 329:1073.</a></li><li><a class="nounderline abstract_t">Gorelik M, Ahmad M, Grossman D, et al. Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors: Who, When, and How to Treat? Surg Clin North Am 2018; 98:157.</a></li><li><a class="nounderline abstract_t">Biomarkers Definitions Working Group.. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89.</a></li><li><a class="nounderline abstract_t">Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134.</a></li><li><a class="nounderline abstract_t">Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol 2012; 26:791.</a></li><li><a class="nounderline abstract_t">Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol 2018; 14:656.</a></li><li><a class="nounderline abstract_t">Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999; 86:858.</a></li><li><a class="nounderline abstract_t">Faiss S, Pape UF, Böhmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689.</a></li><li><a class="nounderline abstract_t">Welin S, Stridsberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009; 89:302.</a></li><li><a class="nounderline abstract_t">Brizzi MP, Berruti A, Ferrero A, et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 2009; 9:388.</a></li><li><a class="nounderline abstract_t">Vezzosi D, Walter T, Laplanche A, et al. Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers 2011; 26:94.</a></li><li><a class="nounderline abstract_t">Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011; 96:3741.</a></li><li><a class="nounderline abstract_t">Laskaratos FM, Walker M, Naik K, et al. Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours. Br J Cancer 2016; 115:1321.</a></li><li><a class="nounderline abstract_t">Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656.</a></li><li><a class="nounderline abstract_t">Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376:125.</a></li><li><a class="nounderline abstract_t">Walter T, Chardon L, Chopin-laly X, et al. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer 2012; 48:1766.</a></li><li><a class="nounderline abstract_t">Stridsberg M, Oberg K, Li Q, et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144:49.</a></li><li><a class="nounderline abstract_t">Calhoun K, Toth-Fejel S, Cheek J, Pommier R. Serum peptide profiles in patients with carcinoid tumors. Am J Surg 2003; 186:28.</a></li><li><a class="nounderline abstract_t">Jensen KH, Hilsted L, Jensen C, et al. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scand J Gastroenterol 2013; 48:70.</a></li><li><a class="nounderline abstract_t">de Laat JM, Pieterman CR, Weijmans M, et al. Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. J Clin Endocrinol Metab 2013; 98:4143.</a></li><li><a class="nounderline abstract_t">Marotta V, Nuzzo V, Ferrara T, et al. Limitations of Chromogranin A in clinical practice. Biomarkers 2012; 17:186.</a></li><li><a class="nounderline abstract_t">Pulvirenti A, Rao D, Mcintyre CA, et al. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford) 2019; 21:612.</a></li><li><a class="nounderline abstract_t">Yang X, Yang Y, Li Z, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One 2015; 10:e0124884.</a></li><li><a class="nounderline abstract_t">Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25:1967.</a></li><li><a class="nounderline abstract_t">Koenig A, Krug S, Mueller D, et al. Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms. PLoS One 2017; 12:e0188876.</a></li><li><a class="nounderline abstract_t">Mosli HH, Dennis A, Kocha W, et al. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. J Clin Endocrinol Metab 2012; 97:E1731.</a></li><li><a class="nounderline abstract_t">Lawrence B, Gustafsson BI, Kidd M, et al. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40:111.</a></li><li><a class="nounderline abstract_t">Wang YH, Yang QC, Lin Y, et al. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine (Baltimore) 2014; 93:e247.</a></li><li><a class="nounderline abstract_t">Oberg K. Management of neuroendocrine tumours. Ann Oncol 2004; 15 Suppl 4:iv293.</a></li><li><a class="nounderline abstract_t">Påhlman S, Esscher T, Bergvall P, Odelstad L. Purification and characterization of human neuron-specific enolase: radioimmunoassay development. Tumour Biol 1984; 5:127.</a></li><li><a class="nounderline abstract_t">Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78:1102.</a></li><li><a class="nounderline abstract_t">Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82:2622.</a></li><li class="breakAll">Vinik A, Feliberti E, Perry RR. Pancreatic Polypeptide (PPoma). In: Endotext, K.R. Feingold, Anawalt B, Boyce A, et al (Eds), MDText.com, Inc, 2000.</li><li><a class="nounderline abstract_t">Larsson LI, Sundler F, Håkanson R. Pancreatic polypeptide - a postulated new hormone: identification of its cellular storage site by light and electron microscopic immunocytochemistry. Diabetologia 1976; 12:211.</a></li><li><a class="nounderline abstract_t">Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469.</a></li><li><a class="nounderline abstract_t">Schmidt WE, Creutzfeldt W. Pancreastatin--a novel regulatory peptide? Acta Oncol 1991; 30:441.</a></li><li><a class="nounderline abstract_t">Ito T, Igarashi H, Jensen RT. Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas 2012; 41:505.</a></li><li><a class="nounderline abstract_t">Tran CG, Sherman SK, Scott AT, et al. It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021; 28:732.</a></li><li><a class="nounderline abstract_t">Strosberg D, Schneider EB, Onesti J, et al. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors. Ann Surg Oncol 2018; 25:3613.</a></li><li><a class="nounderline abstract_t">Rustagi S, Warner RR, Divino CM. Serum pancreastatin: the next predictive neuroendocrine tumor marker. J Surg Oncol 2013; 108:126.</a></li><li><a class="nounderline abstract_t">Sherman SK, Maxwell JE, O'Dorisio MS, et al. Pancreastatin predicts survival in neuroendocrine tumors. Ann Surg Oncol 2014; 21:2971.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/#site (Accessed on March 24, 2021).</li><li><a class="nounderline abstract_t">Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 2017; 46:707.</a></li><li><a class="nounderline abstract_t">Halfdanarson TR, Strosberg JR, Tang L, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020; 49:863.</a></li><li><a class="nounderline abstract_t">Singh S, Moody L, Chan DL, et al. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol 2018; 4:1597.</a></li><li><a class="nounderline abstract_t">Singh S, Bergsland EK, Card CM, et al. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. J Thorac Oncol 2020; 15:1577.</a></li><li><a class="nounderline abstract_t">Oberg K, Couvelard A, Delle Fave G, et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Neuroendocrinology 2017; 105:201.</a></li><li><a class="nounderline abstract_t">Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 2010; 29:19.</a></li><li><a class="nounderline abstract_t">Sansone A, Lauretta R, Vottari S, et al. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers (Basel) 2019; 11.</a></li><li><a class="nounderline abstract_t">Grahame-Smith DG. Progress report: the carcinoid syndrome. Gut 1970; 11:189.</a></li><li><a class="nounderline abstract_t">Buchanan-Hughes A, Pashley A, Feuilly M, et al. Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review. Neuroendocrinology 2021; 111:1.</a></li><li><a class="nounderline abstract_t">Zuetenhorst JM, Bonfrer JM, Korse CM, et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003; 97:1609.</a></li><li><a class="nounderline abstract_t">Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995; 92:790.</a></li><li><a class="nounderline abstract_t">Kema IP, Schellings AM, Meiborg G, et al. Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clin Chem 1992; 38:1730.</a></li><li><a class="nounderline abstract_t">Feldman JM, O'Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986; 81:41.</a></li><li><a class="nounderline abstract_t">Feldman JM. Carcinoid tumors and syndrome. Semin Oncol 1987; 14:237.</a></li><li><a class="nounderline abstract_t">Meijer WG, Kema IP, Volmer M, et al. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 2000; 46:1588.</a></li><li><a class="nounderline abstract_t">Scarpa M, Prando D, Pozza A, et al. A systematic review of diagnostic procedures to detect midgut neuroendocrine tumors. J Surg Oncol 2010; 102:877.</a></li><li><a class="nounderline abstract_t">Zandee WT, Kamp K, van Adrichem RC, et al. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. Eur J Endocrinol 2016; 175:361.</a></li><li><a class="nounderline abstract_t">Adaway JE, Dobson R, Walsh J, et al. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem 2016; 53:554.</a></li><li><a class="nounderline abstract_t">Tellez MR, Mamikunian G, O'Dorisio TM, et al. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas 2013; 42:405.</a></li><li><a class="nounderline abstract_t">Carling RS, Degg TJ, Allen KR, et al. Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem 2002; 39:577.</a></li><li><a class="nounderline abstract_t">Bhattacharyya S, Toumpanakis C, Chilkunda D, et al. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol 2011; 107:1221.</a></li><li><a class="nounderline abstract_t">Dobson R, Burgess MI, Banks M, et al. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One 2013; 8:e73679.</a></li><li><a class="nounderline abstract_t">Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol 2008; 102:938.</a></li><li><a class="nounderline abstract_t">Granberg D. Biochemical Testing in Patients with Neuroendocrine Tumors. Front Horm Res 2015; 44:24.</a></li><li><a class="nounderline abstract_t">Varro A, Ardill JE. Gastrin: an analytical review. Ann Clin Biochem 2003; 40:472.</a></li><li><a class="nounderline abstract_t">Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006; 85:295.</a></li><li><a class="nounderline abstract_t">Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006; 85:331.</a></li><li><a class="nounderline abstract_t">Niederle B, Selberherr A, Bartsch DK, et al. Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Neuroendocrinology 2021; 111:609.</a></li><li><a class="nounderline abstract_t">Kaufmann JE, Irminger JC, Halban PA. Sequence requirements for proinsulin processing at the B-chain/C-peptide junction. Biochem J 1995; 310 ( Pt 3):869.</a></li><li><a class="nounderline abstract_t">de Herder WW, Niederle B, Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84:183.</a></li><li><a class="nounderline abstract_t">Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med 1999; 106:307.</a></li><li><a class="nounderline abstract_t">Hirshberg B, Livi A, Bartlett DL, et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 2000; 85:3222.</a></li><li><a class="nounderline abstract_t">Service FJ, Natt N. The prolonged fast. J Clin Endocrinol Metab 2000; 85:3973.</a></li><li><a class="nounderline abstract_t">van Bon AC, Benhadi N, Endert E, et al. Evaluation of endocrine tests. D: the prolonged fasting test for insulinoma. Neth J Med 2009; 67:274.</a></li><li><a class="nounderline abstract_t">Yu R, Nissen NN, Hendifar A, et al. A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series. Pancreas 2017; 46:48.</a></li><li><a class="nounderline abstract_t">Sada A, Yamashita TS, Glasgow AE, et al. Comparison of benign and malignant insulinoma. Am J Surg 2021; 221:437.</a></li><li><a class="nounderline abstract_t">Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr Res 2011; 36:35.</a></li><li><a class="nounderline abstract_t">Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998; 124:1050.</a></li><li><a class="nounderline abstract_t">Modlin IM, Drozdov I, Kidd M. Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility. Clin Chem Lab Med 2014; 52:419.</a></li><li><a class="nounderline abstract_t">Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer 2015; 22:561.</a></li><li><a class="nounderline abstract_t">Öberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol 2020; 31:202.</a></li><li><a class="nounderline abstract_t">Modlin IM, Drozdov I, Bodei L, Kidd M. Blood transcript analysis and metastatic recurrent small bowel carcinoid management. BMC Cancer 2014; 14:564.</a></li><li><a class="nounderline abstract_t">Modlin IM, Aslanian H, Bodei L, et al. A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors. Endocr Connect 2014; 3:215.</a></li><li><a class="nounderline abstract_t">Modlin IM, Drozdov I, Alaimo D, et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr Relat Cancer 2014; 21:615.</a></li><li><a class="nounderline abstract_t">Modlin IM, Drozdov I, Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One 2013; 8:e63364.</a></li><li><a class="nounderline abstract_t">Modlin IM, Kidd M, Bodei L, et al. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol 2015; 110:1223.</a></li><li><a class="nounderline abstract_t">Partelli S, Andreasi V, Muffatti F, et al. Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2020; 27:3928.</a></li><li><a class="nounderline abstract_t">Liu E, Paulson S, Gulati A, et al. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study. Oncologist 2019; 24:783.</a></li><li><a class="nounderline abstract_t">van Treijen MJC, Korse CM, van Leeuwaarde RS, et al. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study. Front Endocrinol (Lausanne) 2018; 9:740.</a></li><li><a class="nounderline abstract_t">Malczewska A, Witkowska M, Makulik K, et al. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocr Connect 2019.</a></li><li><a class="nounderline abstract_t">Bodei L, Kidd M, Modlin IM, et al. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. Eur J Nucl Med Mol Imaging 2015; 42:1341.</a></li><li><a class="nounderline abstract_t">Pavel M, Jann H, Prasad V, et al. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. Neuroendocrinology 2017; 104:170.</a></li><li><a class="nounderline abstract_t">Al-Toubah T, Cives M, Valone T, et al. Sensitivity and Specificity of the NETest: A Validation Study. Neuroendocrinology 2021; 111:580.</a></li><li><a class="nounderline abstract_t">Bodei L, Kidd M, Modlin IM, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2016; 43:839.</a></li><li><a class="nounderline abstract_t">Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, et al. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy. J Clin Endocrinol Metab 2015; 100:E1437.</a></li><li><a class="nounderline abstract_t">Bodei L, Kidd MS, Singh A, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging 2020; 47:895.</a></li><li><a class="nounderline abstract_t">Modlin IM, Frilling A, Salem RR, et al. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery 2016; 159:336.</a></li><li><a class="nounderline abstract_t">Kidd M, Modlin IM. Therapy: The role of liquid biopsies to manage and predict PRRT for NETs. Nat Rev Gastroenterol Hepatol 2017; 14:331.</a></li></ol></div><div id="topicVersionRevision">Topic 130551 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30295930" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gastroenteropancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1677058" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477712" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gastrinomas: advances in diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13571250" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15538929" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The glucagonoma syndrome and necrolytic migratory erythema: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29629316" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of functional neuroendocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4730072" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The malignant carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8371728" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29191272" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors: Who, When, and How to Treat?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11240971" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12646671" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The chromogranin-secretogranin family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582919" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30158549" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Role of biomarker tests for diagnosis of neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10463986" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860945" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19176944" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886987" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21574156" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21994954" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27811856" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704057" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28076709" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22133573" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7891024" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12842744" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Serum peptide profiles in patients with carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23094948" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23956349" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22303881" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Limitations of Chromogranin A in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30366884" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25894842" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17513802" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chromogranin A: is it a useful marker of neuroendocrine tumors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29232390" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723311" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349414" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25501094" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477324" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Management of neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6505548" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Purification and characterization of human neuron-specific enolase: radioimmunoassay development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9792158" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253344" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253344" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/782992" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pancreatic polypeptide - a postulated new hormone: identification of its cellular storage site by light and electron microscopic immunocytochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703061" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1854501" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pancreastatin--a novel regulatory peptide?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504376" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32656719" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30182331" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775817" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Serum pancreastatin: the next predictive neuroendocrine tumor marker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24752611" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pancreastatin predicts survival in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24752611" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pancreastatin predicts survival in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28609356" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32675783" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30054622" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663527" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28391265" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20196864" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31382663" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4913426" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Progress report: the carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32097914" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12655516" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7641358" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1382000" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2432780" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2442815" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Carcinoid tumors and syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017936" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Discriminating capacity of indole markers in the diagnosis of carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20812262" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A systematic review of diagnostic procedures to detect midgut neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27491374" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438520" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23160483" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12564839" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296329" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Risk factors for the development and progression of carcinoid heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24069222" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18805126" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26303702" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Biochemical Testing in Patients with Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14503984" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Gastrin: an analytical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108778" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108779" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32971521" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575420" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Sequence requirements for proinsulin processing at the B-chain/C-peptide junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17312378" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Well-differentiated pancreatic tumor/carcinoma: insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190379" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Neuroglycopenic and other symptoms in patients with insulinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10999812" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Forty-eight-hour fast: the diagnostic test for insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095416" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The prolonged fast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687521" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Evaluation of endocrine tests. D: the prolonged fasting test for insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27984486" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32873371" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparison of benign and malignant insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21226566" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854582" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24127543" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26037279" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31959337" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25095873" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Blood transcript analysis and metastatic recurrent small bowel carcinoid management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25316294" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25015994" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23691035" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26032155" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32253675" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30158287" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30564197" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30865931" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25947577" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Gene transcript analysis blood values correlate with⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27078712" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32615553" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Sensitivity and Specificity of the NETest: A Validation Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26596723" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26348352" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838581" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26456125" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28293026" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Therapy: The role of liquid biopsies to manage and predict PRRT for NETs.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
